Insulin glargine: The first clinically useful extended-action insulin analogue

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 11, 2001, Pages 1891-1902

  Ashwell, S G ^a   Home, P D ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Diabetes mellitus; Insulin glargine; Insulin therapy

Indexed keywords

HEMOGLOBIN A1C; INSULIN DERIVATIVE; INSULIN GLARGINE; ISOPHANE INSULIN; RECOMBINANT DNA;

ADOLESCENT; AMINO ACID SUBSTITUTION; ARTICLE; BETA CHAIN; BLOOD GLUCOSE MONITORING; CARBOXY TERMINAL SEQUENCE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG ABSORPTION; DRUG MECHANISM; HUMAN; HYPOGLYCEMIA; INJECTION SITE; INSULIN DEPENDENT DIABETES MELLITUS; ISOELECTRIC POINT; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; TITRIMETRY;

ANIMALS; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 0035171247     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.11.1891     Document Type: Article

References (56)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
2. Insulin analogues
3. The physiologic replacement of insulin: An elusive goal
4. Insulin glargine: The first clinically useful extended acting insulin in half a century?
5. The action profiles of human NPH insulin preparations
6. Study of porcine and human isophane (NPH) insulins in normal subjects
7. Improving insulin therapy: Achievements and targets
8. Clinical pharmacology of human insulin
9. 125I-insulin absorption and blood glucose concentration
10. Inadequate suspension of neutral protamine Hagedorn (NPH) insulin in pens
11. NovoSol Basal: Pharmacokinetics of a novel soluble long acting insulin analogue
12. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs
13. Long-acting insulin analogs
14. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304
15. A randomised three period crossover trial investigating the effect of subcutaneous insulin detemir and human insulin on glucose metabolism in healthy subjects
16. Reduced pharmacokinetic (PK) variability of a novel, long-acting insulin analogue
17. Effect of adequate vs. inadequate resuspension of NPH insulin prior to s.c. injection on pharmacokinetics and -dynamics in T1DM
18. Pharmacokinetic and glucodynamic assessments of M-Palmitol Lys (B29) human insulin in healthy volunteers
19. Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogs
20. Insulin glargine is not carcinogenic in rats and mice
21. 6 insulin hexamers
22. New insulin preparations with prolonged action profiles: A21-modified arginine insulins
23. Comparison of the pharmacokinetics/dynamics of Gly(A21) Arg(B21, B32) human insulin (HOE71GT) with NPH insulin following subcutaneous injection by using euglycaemic clamp technique
24. Pharmacokinetics of a 'long-acting' human insulin analogue (HOE 901) in healthy subjects
25. 125I-labelled insulin glargine (HOE 901) in healthy men
26. Time-action profile of the long-acting insulin analogue HOE 901
27. Time-action profile of insulin glargine (HOE 901) in Japanese volunteers
28. Profile of action of biosynthetic long-acting insulin (HOE901) tested in normal volunteers by glucose clamp methodology
29. Time-action profile of the long-acting insulin analog insulin glargine (HOE 901) in comparison with those of nph insulin and placebo
30. An assessment of the variability in the pharmacodynamics (glucose lowering effect) of HOE 901 compared to NPH and ultralente human insulins using the euglycaemic clamp technique
31. Pharmacokinetics and dynamics of s.c. injection of the long-acting insulin glargine (HOE 901) in T1DM
32. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente insulin and continuous subcutaneous infusion of insulin lispro
33. Comparison of the sc. absorption of HOE 901 and NPH human insulin in Type 2 diabetic subjects
34. Efficacy and safety of HOE 901 versus NPH insulin in patients with Type 1 diabetes
35. Basal insulin glargine (HOE 901) versus NPH insulin in patients with Type 1 diabetes on multiple daily insulin regimens
36. Less hypoglycaemia with insulin glargine in intensive insulin therapy for Type 1 diabetes
37. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with Type 1 diabetes
38. A new long-acting insulin (HOE 901) demonstrates less nocturnal hypoglycaemia when compared with protamine insulin in a clinical trial
39. Insulin glargine (HOE 901) lowers fasting blood glucose in children with Type 1 diabetes mellitus without increasing the risk of hypoglycaemia
40. Nocturnal glucose control and free insulin levels in children with Type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen
41. Less nocturnal hypoglycaemia and better post-dinner glucose control with insulin-glargine compared with bedtime NPH insulin combination therapy in type 2 diabetes
42. The effect of HOE 901 on glycaemic control in Type 2 diabetes
43. Basal insulin therapy in Type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH
44. Less nocturnal hypoglycaemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in Type 2 diabetes
45. HOE 901 (insulin glargine) improves satisfaction with intensified insulin treatment for Type 1 diabetes
46. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes
47. The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake
48. Carcinogenic effect on female rats after 12 months administration of the insulin analogue B10 Asp
49. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use
50. Effects of insulin glargine, human insulin and the insulin analogue Asp(B10) on the insulin receptor signalling cascade
51. Growth promoting and metabolic activity of the human insulin analogue [GlyA21, ArgB31, ArgB32] insulin (HOE 901) in muscle cells
52. Efficacy and safety of 6-month treatment with insulin detemir in Type 1 diabetic patients on a basal/bolus regimen
53. The long acting human insulin analog HOE 901: Characteristics of insulin signalling in comparison to Asp(B10) and regular insulin
54. Effects of the long acting insulin analog insulin glargine on cultured human skeletal muscle cells: Comparisons to insulin and IGF-1
55. Cotherapy with recombinant human insulin-like growth factor 1 and insulin improves glycaemic control in Type 1 diabetes
56. Progression of retinopathy with insulin glargine or NPH insulin - A multi-trial analysis